Clin2
NCT07288073Possibly a fitRecruiting

TIL Therapy for Advanced Skin Cancer Patients

Cutaneous Squamous Cell CarcinomaMerkel Cell CarcinomaMetastatic Cutaneous Squamous Cell CarcinomaSkin Cancer

Treatments studied

Part of Cancer, Infections, Skin clinical trials.

This study tests a personalized cell therapy called TIL (tumor-infiltrating lymphocytes) for people with advanced skin cancers that have not responded to immunotherapy. Doctors take your tumor cells, grow immune cells from them, and then infuse them back to fight the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
14 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must have a type of skin cancer called cutaneous squamous cell carcinoma or Merkel cell carcinoma that has spread or come back.
  • Your cancer must have gotten worse after trying immunotherapy drugs like Keytruda or Opdivo.
  • You need at least one tumor that is large enough (about half an inch) for doctors to remove and make into a personalized cell treatment.
  • You should be generally up and about and able to take care of yourself (ECOG score 0-2).
  • Your heart, lungs, and blood counts must be in good enough shape to handle the treatment.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07651618Not yet recruiting· Phase 2
Cell Therapy for Melanoma Resistant to Checkpoint Inhibitors

This trial tests a new treatment called tumor infiltrating lymphocyte (TIL) therapy for melanoma that hasn't responded to standard immunotherapy drugs. The therapy involves taking immune cells from your tumor, growing more of them in the lab, and putting them back into your body to fight the cancer.

Perth, Western Australia
NCT07028008Not yet recruiting
TIL therapy for advanced melanoma after immunotherapy

This trial tests a personalized cell therapy using your own immune cells (TILs) grown in a lab. It is for people with advanced melanoma that did not respond to or stopped responding to prior immunotherapy.

NCT07406724Not yet recruiting· Phase 2
TIL therapy vs chemo for advanced melanoma

This trial tests a personalized cell therapy using your own immune cells (tumor-infiltrating lymphocytes, or TILs) to fight advanced melanoma that has stopped responding to standard treatments like anti-PD-1 (immunotherapy). If you qualify, you'd receive your own TILs instead of chemotherapy.

NCT06783270Recruiting· Phase 1
T-Cell Therapy for Advanced Melanoma

This trial tests a new T-cell therapy made from your own tumor (TILs), genetically edited to remove the PD1 checkpoint blocker. It may help your immune system fight melanoma that has not responded to standard treatments like anti-PD1 therapy.

Herlev, Capital Region
NCT06532812Recruiting· Phase 1/Phase 2
TIL therapy plus immunotherapy for advanced breast cancer

This trial tests a personalized therapy using your own immune cells (TILs) combined with immunotherapy to fight advanced breast cancer that has not responded to other treatments. It may help if you have a tumor that can be biopsied and you are generally healthy enough for the procedures.

Beijing, Beijing Municipality
NCT05087745Recruiting· Early Phase 1
TIL therapy for advanced solid tumors

This trial tests a treatment that uses your own immune cells, called TILs, to fight advanced solid tumors. The cells are taken from a biopsy of your tumor, multiplied in a lab, and then given back to you. It might help if you have tried other treatments without success, or if no standard treatment is available.

Hangzhou, Zhejiang

Hear when a new Cutaneous Squamous Cell Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.